Related references
Note: Only part of the references are listed.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
First Case of 2019 Novel Coronavirus in the United States
Michelle L. Holshue et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Emmie de Wit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Timothy P. Sheahan et al.
NATURE COMMUNICATIONS (2020)
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Yan Gao et al.
SCIENCE (2020)
Angiotensin-converting enzyme 2 (ACE2),SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)
Arno R. Bourgonje et al.
JOURNAL OF PATHOLOGY (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
Richard T. Eastman et al.
ACS CENTRAL SCIENCE (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Droplets and Aerosols in the Transmission of SARS-CoV-2
Matthew Meselson
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2
Chiara Robba et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2020)
Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis
Leiwen Fu et al.
JOURNAL OF INFECTION (2020)
Remdesivir: A beacon of hope from Ebola virus disease toCOVID-19
Ali Nili et al.
REVIEWS IN MEDICAL VIROLOGY (2020)
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Christoph D. Spinner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Giovanni Guaraldi et al.
LANCET RHEUMATOLOGY (2020)
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Sabue Mulangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini et al.
MBIO (2018)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
Michael K. Lo et al.
SCIENTIFIC REPORTS (2017)
Network meta-analysis: application and practice using Stata
Sungryul Shim et al.
EPIDEMIOLOGY AND HEALTH (2017)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in coronavirus RNA synthesis
E Minskaia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Exoribonuclease superfamilies: structural analysis and phylogenetic distribution
YH Zuo et al.
NUCLEIC ACIDS RESEARCH (2001)
Share Paper
